Home › Compare › SYRS vs FCPT

SYRS vs FCPT: Dividend Comparison 2026

SYRS yields 1000000.00% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYRS wins by $4.7683925249533696e+36M in total portfolio value
10 years
SYRS
SYRS
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full SYRS calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — SYRS vs FCPT

📍 SYRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYRSFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYRS + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SYRS pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYRS
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, SYRS beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYRS + FCPT for your $10,000?

SYRS: 50%FCPT: 50%
100% FCPT50/50100% SYRS
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

SYRS
Analyst Ratings
4
Buy
5
Hold
Consensus: Hold
Price Target
$16.67
+8334900.0% upside vs current
Range: $5.00 — $30.00
Altman Z
-15.5
Piotroski
0/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYRS buys
0
FCPT buys
0
No recent congressional trades found for SYRS or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYRSFCPT
Forward yield1000000.00% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4.7683925249533696e+36M$49.1K ✓
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓$5,775.28
Total dividends collected$4.7683311610149396e+36M$24.1K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$16.67$27.00 ✓

Year-by-year: SYRS vs FCPT ($10,000, DRIP)

YearSYRS PortfolioSYRS Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,401$700.92+$100.00M → SYRS
2$934,786,450,701$934,679,439,252.34$13,064$864.84+$934786.44M → SYRS
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,051$1,072.48+$8165787108.56M → SYRS
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$17,442$1,337.22+$66665884190957.63M → SYRS
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$20,340$1,677.08+$508662171058048128.00M → SYRS
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$23,880$2,116.57+$3.62723524842849e+21M → SYRS
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$28,241$2,689.36+$2.417368115915061e+25M → SYRS
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$33,660$3,442.07+$1.5056740286145463e+29M → SYRS
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$40,456$4,439.95+$8.764771002818475e+32M → SYRS
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$49,063$5,775.28+$4.7683925249533696e+36M → SYRS

SYRS vs FCPT: Complete Analysis 2026

SYRS — Stock

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Full SYRS Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this SYRS vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYRS vs SCHDSYRS vs JEPISYRS vs OSYRS vs KOSYRS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.